
Sign up to save your podcasts
Or


Companies are spending big bucks advertising weight-loss drugs like Rybelsus, seeing huge potential in capitalizing on the popularity of Ozempic. But in Canada, so-called "reminder ads" can give only the name of the medication, not what it's for, telling people to ask their doctor for details. Ad man Terry O’Reilly says it can result in bad ads that turn people off, and pharmaceutical policy expert Barbara Mintzes says reminder ads can lead to overtreatment and high costs, doing more harm than good.
By CBC4.8
6262 ratings
Companies are spending big bucks advertising weight-loss drugs like Rybelsus, seeing huge potential in capitalizing on the popularity of Ozempic. But in Canada, so-called "reminder ads" can give only the name of the medication, not what it's for, telling people to ask their doctor for details. Ad man Terry O’Reilly says it can result in bad ads that turn people off, and pharmaceutical policy expert Barbara Mintzes says reminder ads can lead to overtreatment and high costs, doing more harm than good.

433 Listeners

383 Listeners

162 Listeners

175 Listeners

371 Listeners

197 Listeners

70 Listeners

781 Listeners

474 Listeners

280 Listeners

218 Listeners

20 Listeners

415 Listeners

26 Listeners

104 Listeners

69 Listeners

171 Listeners

0 Listeners

118 Listeners

292 Listeners

2 Listeners

5 Listeners